- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Journal: Fiasp Confused with NovoLOG. (Pubmed Central) - Nov 29, 2021 Key Words: Fast acting insulin aspart, Medtronic 670G hybrid closed loop, Type 1 Diabetes. No abstract available
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Journal: Fast-Acting Insulin Aspart Use with the MiniMed™ 670G System. (Pubmed Central) - Oct 20, 2021 Paired analysis for matched breakfast meals revealed no significant differences in time to maximum glucose, peak glucose or glucose excursion. CONCLUSIONS In this pilot study the use of either Novolog® or Fiasp® in a commercially available MiniMed™ 670G system operating in Auto Mode resulted in clinically similar glycemic outcomes, with a slight increase in daily insulin requirements using Fiasp®.
- |||||||||| LAI287/semaglutide (LAIsema) / Novo Nordisk, insulin icodec (OI287GT) / Novo Nordisk
New P3 trial: A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3) Klinikai vizsgálat annak tanulmányozására, hogy az IcoSema, az ikodek inzulin és a szemaglutid kombinációjából álló, hetente alkalmazott új gyógyszer mennyire kontrollálja jól a 2-es típusú cukorbetegek vércukorszintjét a naponta, aszpart inzulinnal együtt alkalmazott glargin inzulinnal összehasonlítva (COMBINE 3) (EUDRACT) - Oct 17, 2021 P3, N=680, Ongoing,
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Metastases: FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) - Sep 30, 2021 P=N/A, N=30, Completed, SAR-Asp and NN-Asp demonstrated similar efficacy and safety (including immunogenicity) in people with diabetes over 12 months treatment. Recruiting --> Completed
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open, Combination therapy: Afrezza (clinicaltrials.gov) - Sep 21, 2021 P3, N=264, Recruiting, Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) (clinicaltrials.gov) - Aug 26, 2021 P=N/A, N=75, Active, not recruiting, Trial completion date: Oct 2022 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Apr 2022 Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Sep 2021
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion date, Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Aug 23, 2021 P3, N=264, Not yet recruiting, Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Sep 2021 Trial completion date: Apr 2025 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Apr 2023
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, ultra-rapid acting insulin (AT247) / Arecor, NovoLog (insulin aspart) / Novo Nordisk
Clinical, PK/PD data, Journal: Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-blind, Crossover Study in Men With Type 1 Diabetes. (Pubmed Central) - Aug 22, 2021 AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with IAsp and faster IAsp. It therefore represents a promising candidate in the pursuit for second generation prandial insulin analogs to improve postprandial glycemic control.
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment change: Evaluation of Fiasp (clinicaltrials.gov) - Aug 18, 2021 P4, N=27, Completed, It therefore represents a promising candidate in the pursuit for second generation prandial insulin analogs to improve postprandial glycemic control. N=20 --> 27
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Clinical, Journal: The complexities of insulin allergy: a case and approach. (Pubmed Central) - Jul 31, 2021 Therapeutic strategies include avoidance and insulin alternatives, alternate insulin preparations, or desensitization. In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective.
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
New P3 trial, Combination therapy: Afrezza (clinicaltrials.gov) - Jul 22, 2021 P3, N=264, Not yet recruiting,
- |||||||||| ultra-rapid-acting concentrated insulin aspart (AT278) / Arecor
Trial completion: AT278 and NovoRapid (clinicaltrials.gov) - Jul 20, 2021 P1, N=38, Completed, In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective. Recruiting --> Completed
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Infusion Set Survival and Performance during the Medtronic Extended-Wear Infusion Set (EWIS) Pivotal Trial () - May 29, 2021 - Abstract #ADA2021ADA_1926; P=N/A This multi-center (15), single-arm, non-randomized, non-inferiority trial in 259 participants (18-80yrs) with T1D using the MiniMed™ 670G system (with Humalog™ or Novolog™ insulin) involved wearing a 2- or 3-day IS for 2 weeks (run-in) followed by 12 consecutive EWIS wears (study phase)... The 7-day EWIS was safe and its performance was superior at ≥174 hours compared to the performance observed for 2- or 3-day infusion sets.
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Reported Satisfaction during the Medtronic Extended-Wear Infusion Set (EWIS) Pivotal Trial () - May 29, 2021 - Abstract #ADA2021ADA_1702; P=N/A This multi-center (15), single-arm, non-randomized, non-inferiority trial in 259 participants (18-80yrs) with T1D using the MiniMed™ 670G system (with Humalog™ or Novolog™ insulin) involved wearing a 2- or 3-day IS for 2 weeks (run-in) followed by 12 consecutive EWIS wears (study phase)... These findings point to significantly greater satisfaction with the EWIS when compared with a 2- or 3-day IS, which may result in reduced care burden and improved adherence.
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Preclinical Study of a Combined Insulin Infusion and Glucose Sensing Device (Duo) () - May 29, 2021 - Abstract #ADA2021ADA_1069; The results indicated that no interference of sensor signals was observed from insulin infused though the cannula of the same Duo set in the near proximity or from mechanical inference from the infusion-set movements. These data confirm the feasibility of a combined 7-day set which simultaneously infuses insulin and senses glucose subcutaneously in a T1D porcine model.
- |||||||||| IDegLira (insulin degludec/liraglutide) / Novo Nordisk
Enrollment open: IDegLira HIGH Trial (clinicaltrials.gov) - May 26, 2021 P3, N=140, Recruiting, These data confirm the feasibility of a combined 7-day set which simultaneously infuses insulin and senses glucose subcutaneously in a T1D porcine model. Active, not recruiting --> Recruiting
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Phase classification, Metastases: FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) - May 13, 2021 P=N/A, N=33, Recruiting, The simulation studies indicate that using Fiasp® in place of NovoLog® with the MiniMed 670G system will significantly improve the time spent in the healthy, euglycemic range and reduce exposure to hyperglycemia and hypoglycemia in most patients. Phase classification: P4 --> P=N/A
- |||||||||| Trial primary completion date: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=150, Active, not recruiting, We concluded that the studied IAsp biosimilar (RD10046) was bioequivalent to NovoRapid. Trial primary completion date: Dec 2020 --> Oct 2021
|